Skip to main content

Table 4 Estimates of annual acquisition cost of biologic and non-biologic agents

From: Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia

Medication

DDDa

Adm. Ra

Price (US Dollars)

Annual costd (US Dollars)

Biological agents

 Infliximab

3.75 mg

Parenteral

16.50

6023

 Adalimumab

2.9 mg

Parenteral

44.54

16,258

 Certolizumab

14 mg

Parenteral

37.98

13,865

 Golimumab

1.66 mg

Parenteral

21.99

8025

 Ustekinumab

0.54 mg

Parenteral

12.25

4470

 Vedolizumab

5.4 mg

Parenteral

45.84

16,730

Non-biological agents

 Azathioprine

0.15 g

Oral

0.69

254.64

 Mercaptopurine

105 mgb

Oral

1.12

408.8

 Methotrexate

2.5 mg

Oral

1.44

526.82

Parenteral

0.24

87.41

 Sulfasalazine

2 g

Oral

0.30

110.37

 Mesalazine

1.5 g

Oral

1.16

425.69

Rectal

2.67

976.98

 Prednisone

10 mg

Oral

0.04

16.06

 Prednisolone

10 mg

Oral

0.185

67.64

Parenteral

0.52

189

 Hydrocortisone

30 mg

Oral

0.12

45.33

Parenteral

0.65

237

 Budesonide

9 mg

Oral

c

c

 Metronidazole

2 g

Oral

0.37

138.21

1.5 g

Parenteral

6.51

2378.88

 Ciprofloxacin

1 g

Oral

1.24

455.52

0.5 g

Parenteral

4.19

1529

  1. aDDD defined daily dose, Adm. R route of administration
  2. bCalculated from usual maintenance dose 1–2.5 mg/kg
  3. cThe price of that specific dosage form is not available in the SFDA drug list
  4. dRounded to the nearest dollar